MedTrace Logo

Once-a-day Tacrolimus Conversion Study: The OneTAC Trial

NCT02545972 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2016-09-21

No results posted yet for this study

Summary

This study investigates the use of tacrolimus extended release in stable patients who have undergone a heart transplant. All patients will receive the study medication free of charge for the 1 year duration of the study.

Conditions

Interventions

DRUG

tacrolimus extended release

daily dosing of tacrolimus

Sponsors & Collaborators

  • Newark Beth Israel Medical Center

    lead OTHER

Principal Investigators

  • David A Baran, MD · Newark Beth Israel Medical Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-02-29
Primary Completion
2018-11-30
Completion
2019-02-28

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02545972 on ClinicalTrials.gov